Clinical trials: Adenocarcinoma
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Pancreatic Cancer, PDAC
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 302 (NCT06625320)
- Testing
- RMC-6236, Gemcitabine, nab-paclitaxel
- Where
- 60 sites in United States, France and 5 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Solid Tumor, HER-2 Protein Overexpression
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting…
- Trial name
- NCT03680560
- Testing
- ACTR T Cell Product, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cogent Biosciences, Inc.
Merkel Cell Carcinoma
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR.
- Trial name
- NCT03853317
- Testing
- Avelumab, N-803, haNK™
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Adenocarcinoma, Scirrhous, Linitis Plastica
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
This is a prospective, open-label, single-arm, non-randomized, multi-center, phase II proof of concept (PoC) study with a two-stage design and Bayesian interim monitoring to evaluate efficacy and safety of single agent TKI258 in…
- Conditions
- Adenocarcinoma, Scirrhous, Linitis Plastica, Stomach Neoplasms, Stomach Diseases
- Trial name
- NCT01576380
- Testing
- TKI258
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism, Metastatic Pancreatic Cancer
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
- Conditions
- Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- CATIQ P3 (NCT06861088)
- Testing
- Kinisoquin™
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Quercis Pharma AG
Gastric Cancer
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in…
- Trial name
- DG-03 (NCT04379596)
- Testing
- Fluorouracil (5-FU), Capecitabine, Durvalumab
- Where
- 71 sites in United States, Brazil and 12 more
- Volunteers
- 452 people
- Sponsor
- AstraZeneca
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Carcinoma, Renal Cell
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma
- Trial name
- MACS0460 (NCT00688753)
- Testing
- RAD001
- Where
- 19 sites in Belgium, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Cachexia, Digestive System Cancer
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
- Conditions
- Cachexia, Digestive System Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06940102
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, TKI-Based Therapy
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Renal Cell Carcinoma, First-line Treatment
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
This is a Phase II, open-label trial to evaluate the efficacy and safety of AK104 monotherapy or AK104 in combination with axitinib as a first-line treatment for advanced/metastatic renal cell carcinoma (RCC).
- Trial name
- NCT05256472
- Testing
- AK104, axitinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
Hepatocellular Carcinoma, Fibrolamellar Carcinoma
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.
- Trial name
- NCT05603572
- Testing
- KAT-101, KAT-201
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Primocure Pharma
Pseudomyxoma Peritonei, Peritoneal Cancer
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Pseudomyxoma peritonei (PMP) is an orphan disease, characterized by the progressive accumulation of jelly-like material within the abdomen, which occurs in approximately 2-3 people per million per year.
- Conditions
- Pseudomyxoma Peritonei, Peritoneal Cancer, Mucinous Adenocarcinoma, Mucinous Tumor
- Trial name
- NCT03976973
- Testing
- Bromelain, Acetylcysteine, Interventional radiology insertion of drain
- Volunteers
- 62 people
- Sponsor
- Mucpharm Pty Ltd
Hepatocellular Carcinoma
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
- Trial name
- NCT00627042
- Testing
- Ramucirumab (IMC-1121B)
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Hepatocellular Carcinoma
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness
- Trial name
- NCT02269995
- Testing
- E7040
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.